Keynote Presentation: Molecular Testing for Hereditary-Familial Prostate Cancer and for Risk..

3 Views

07/03/23

Presented At:
Molecular Diagnostics Virtual Eve2018

Presented By:
Judd W Moul, MD, FACS - James H Semans MD Professor of Surgery, Division of Urologic Surgery, Director, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center

Speaker Bio:
Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland and an attending Urologic Oncologist at the Walter Reed Army Medical Center (WRAMC) in Washington, DC. In addition, he was Director of the Center for Prostate Disease Research (CPDR); a Congress-mandated research program of the Department of Defense based at USUHS and WRAMC. In 2004, he completed a 26-year U.S. Army career, retiring as a full Colonel in the Medical Corps, and became Chief of the Division of Urologic Surgery at Duke. Serving as Chief from 2004 to 2011, he brought innovation and growth to the program. Most notably, he started the Duke Prostate Center, expanded the urology residency training program through a novel collaboration with the Department of Defense and was able to maintain Duke Urology as a top 10 program in the nation throughout his tenure.

Webinar:
Keynote Presentation: Molecular Testing for Hereditary-Familial Prostate Cancer and for Risk Assessment in Localized Disease

Webinar Abstract:
Prostate cancer is one of the most common cancers in men and a major health issue in the US and Worldwide. Until recently, prostate cancer was not felt to be a hereditary disease. However, up to 13% of men who present with de novo metastatic disease have a hereditary gene defect and men with a family history are also at risk for hereditary disease. The most common genes linked to hereditary prostate cancer include BRCA2, BRCA2, ATM, and CHEK2. In addition to hereditary genes, somatic mutations are common in advanced and castrate resistant disease and assessment in tumor and metastatic tissue is beginning to dictate novel therapeutics. Measurement of tumor derived messenger RNA expression panels is the basis of a number of commercially available molecular biomarker tests including Prolaris, Oncotype GPS, and Decipher. This presentation will highlight hereditary and somatic tumor testing and current practical considerations for clinical practice.

Earn PACE/CME Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtu....al-event/molecular-d
2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtu....al-event/molecular-d
3. Click Here to get your PACE (Expiration date –April 11, 2020 12:00 PM)– http://www.labroots.com/credit..../pace-credits/2837/t
4. Click here to get your CME credits (Expiration date – 3 months from event) – https://www.surveymonkey.com/r/3N639M6

LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc